482 related articles for article (PubMed ID: 16499995)
1. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
2. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
3. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
Hu Y; McDermott MP; Ahrendt SA
Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients.
Murata M; Tagawa M; Kimura H; Kakisawa K; Shirasawa H; Fujisawa T
Int J Oncol; 1998 Mar; 12(3):577-81. PubMed ID: 9472095
[TBL] [Abstract][Full Text] [Related]
6. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
7. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma.
Liu G; Miller DP; Zhou W; Thurston SW; Fan R; Xu LL; Lynch TJ; Wain JC; Su L; Christiani DC
Cancer Res; 2001 Dec; 61(24):8718-22. PubMed ID: 11751390
[TBL] [Abstract][Full Text] [Related]
8. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
9. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer.
Shih CM; Lee YL; Chiou HL; Hsu WF; Chen WE; Chou MC; Lin LY
Lung Cancer; 2005 Dec; 50(3):291-7. PubMed ID: 16122836
[TBL] [Abstract][Full Text] [Related]
10. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms.
Liu G; Zhou W; Park S; Wang LI; Miller DP; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer; 2004 Dec; 101(12):2802-8. PubMed ID: 15534883
[TBL] [Abstract][Full Text] [Related]
11. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
13. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Mechanic LE; Marrogi AJ; Welsh JA; Bowman ED; Khan MA; Enewold L; Zheng YL; Chanock S; Shields PG; Harris CC
Carcinogenesis; 2005 Mar; 26(3):597-604. PubMed ID: 15564288
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer].
Fang SM; Jin X; Li Y; Wang R; Guo W; Wang N; Zhang JH
Ai Zheng; 2005 Mar; 24(3):305-10. PubMed ID: 15757531
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Fontanini G
Oncol Rep; 2008 Mar; 19(3):771-3. PubMed ID: 18288414
[TBL] [Abstract][Full Text] [Related]
18. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
19. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
[TBL] [Abstract][Full Text] [Related]
20. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer.
Shih CM; Lee YL; Chiou HL; Chen W; Chang GC; Chou MC; Lin LY
Lung Cancer; 2006 Apr; 52(1):15-20. PubMed ID: 16476505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
